Print Page   |   Contact Us   |   Your Cart   |   Sign In
Search
Sign In


Forgot your password?

Haven't registered yet?

Breaking News
Calendar
News & Press: Daily Updates

Dengue Vaccine Enters Phase 3 Trial in Brazil

Friday, January 15, 2016   (0 Comments)

A large-scale clinical trial to evaluate whether a candidate vaccine can prevent the mosquito-borne illness dengue fever has been launched in Brazil. The vaccine, TV003, was developed by scientists in the laboratory of Stephen Whitehead, Ph.D., at NIH’s National Institute of Allergy and Infectious Diseases (NIAID). The Butantan Institute, a non-profit producer of immunobiologic products for Brazil, licensed the NIAID dengue vaccine technology and is sponsoring the placebo-controlled, multi-center Phase 3 trial using test vaccine produced in Sao Paulo.

MORE >>


OSAP Disclaimer | Please notify our webmaster of any problems with this website.
OSAP thanks its Super Sponsors for their support in 2016. Sponsorship does not imply endorsement by OSAP of a company's products or services.